Lineage Cell Therapeutics (LCTX) Income from Non-Controlling Interests (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Income from Non-Controlling Interests of $23000.0 for Q1 2026, up 675.0% year-over-year from $2967.7 in Q1 2025, and down 43.9% quarter-over-quarter from $41000.0 in Q4 2025.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Income from Non-Controlling Interests (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Income from Non-Controlling Interests history runs 17 years deep, the most recent figure standing at $23000.0 for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests rose 675.0% year-over-year to $23000.0; the TTM figure through Mar 2026 stood at $193000.0 (up 394.87% YoY), while the FY2025 annual figure was $166000.0, up 514.81% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at $23000.0, down from $41000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $100000.0 in Q2 2025, with the low at -$48000.0 in Q3 2023.
- The 5-year median for Income from Non-Controlling Interests is -$4000.0 (2025), against an average of $8411.8.
- The sharpest annual moves came in 2023 and 2025: Income from Non-Controlling Interests sank 433.33% in 2023, then soared 869.23% in 2025.
- Lineage Cell Therapeutics' Income from Non-Controlling Interests stood at -$8000.0 in 2022, then soared by 862.5% to $61000.0 in 2023, then sank by 62.3% to $23000.0 in 2024, then soared by 78.26% to $41000.0 in 2025, then tumbled by 43.9% to $23000.0 in 2026.
- Business Quant data shows LCTX's Income from Non-Controlling Interests at $23000.0 in Q1 2026, $41000.0 in Q4 2025, and $29000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | 62,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 62,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 41,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | -13,000.00 |
| Mar 31, 2024 | -16,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Sep 30, 2023 | -48,000.00 |
| Jun 30, 2023 | 26,000.00 |
| Mar 31, 2023 | -32,000.00 |
| Dec 31, 2022 | -8,000.00 |
| Sep 30, 2022 | -47,000.00 |
| Jun 30, 2022 | -19,000.00 |
| Mar 31, 2022 | -6,000.00 |
| Dec 31, 2021 | -200,000.00 |
| Sep 30, 2021 | -11,000.00 |